Pharmacological and chemical effects of cigarette additives

American Journal of Public Health

Volumn 97, Issue 11, 2007, Pages 1981-1991

  Rabinoff, Michael ^a   Caskey, Nicholas ^a,b   Rissling, Anthony ^c   Park, Candice ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6,7,8 TETRAHYDROQUINOXALINE; ACETALDEHYDE; ACONITIC ACID; ALPHA TOCOPHEROL; AMMONIA; ANTIOXIDANT; BETA CAROTENE; CAFFEIC ACID; CINEOLE; EUGENOL; FARNESOL; GAMMA VALEROLACTONE; HUMECTANT; ISOVALERIC ACID; LACTONE DERIVATIVE; LEVULINIC ACID; MENTHOL; NICOTINE; NITROSAMINE; PHENETHYL SALICYLATE; PYRAZINE; PYRIDINE; QUINOXALINE DERIVATIVE; SALICYLIC ACID BENZYL ESTER; SALICYLIC ACID DERIVATIVE; SALICYLIC ACID METHYL ESTER; SUGAR; THIAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIC ACID; NICOTINIC AGENT;

ARTICLE; CACAO; CIGARETTE SMOKING; GLYCYRRHIZA; HEALTH CARE ORGANIZATION; HUMAN; SMOKING; TOBACCO; TOBACCO INDUSTRY; ADDICTION; ANIMAL; BRAIN; CHEMISTRY; COGNITION; DRUG EFFECT; DRUG POTENTIATION; ELECTROENCEPHALOGRAPHY; EVOKED RESPONSE; INDOOR AIR POLLUTION; METABOLISM; PATHOPHYSIOLOGY; PLANT; REVIEW; UNITED STATES;

AMMONIA; ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; COGNITION; DRUG SYNERGISM; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMANS; NICOTINE; NICOTINIC AGONISTS; PLANTS, TOXIC; SMOKING; TOBACCO; TOBACCO INDUSTRY; TOBACCO SMOKE POLLUTION; UNITED STATES;

EID: 35748953798     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2005.078014     Document Type: Article

References (117)

1. Jong-wook L. World Health Organization director general's speech to 12th World Congress on Tobacco and Health, presented on August 4, 2003. Available at: http://www.who.int/dg/lee/speeches/2003/helsinki/en. Accessed June 15, 2005.
2. Peto R, Lopez AD. Future worldwide health effects of current smoking patterns. In: Koop CD, Pearson C, Schwarz MR, eds. Critical Issues in Global Health. New York, NY: Jossey-Bass; 2001.
3. Genetic engineering high nicotine plots. Bates no. 3001191/1212. Available at: http://legacy.library.ucsf.edu/tid/hpl41f00. Accessed June 18, 2004.
4. Genetic engineering of tobacco for nicotine biosynthesis. RJ Reynolds. Bates no. 507029142/9143. Available at: http://legacy.library.ucsf.edu/tid/ jtq34d00. Accessed June 18, 2004.
5. Conkling MA. The molecular genetics of nicotine biosynthesis in tobacco altering nicotine content through genetic engineering. October 1, 1997. Philip Morris. Bates no. 2063655463. Available at: http://legacy.library.ucsf.edu/tid/ wmf67e00. Accessed June 18, 2004.
6. Lewan T. Brazil's secret: crazy tobacco. RJ Reynolds. Bates no. 522608883/8891. Available at: http://legacy.library.ucsf.edu/tid/xoc60d00. Accessed June 18, 2004.
7. Novotny TE, Zhao F. Consumption and production waste: another externality of tobacco use. Tob Control. 1999;8:75-80.
8. Skladanowski MA. Addition of nicotine extract to a blend. January 4, 1977. Lorillard. Bates no. 01305142/5145. Available at: http://legacy.library. ucsf.edu/tid/cvm61e00. Accessed June 18, 2004.
9. Brinkley A. Sam asked me to develop a process description for the high nicotine G-7 sheet and for the heat treated nicotine/extract G-7 sheet. September 27, 1990. RJ Reynolds. Bates no. 508902381/2385. Available at: http://legacy.library.ucsf.edu/tid/fmr83d00. Accessed June 18, 2004.
10. Amos Westmoreland 1991 objectives. RJ Reynolds. Bates no. 509304887/4888. Available at: http://legacy.library.ucsf.edu/tid/cor73d00. Accessed June 18, 2004.
11. KDN effluent/nicotine extract design. February 7, 1991. RJ Reynolds. Bates no. 512846285/6285. Available at: http://legacy.library.ucsf.edu/tid/ osx23d00. Accessed June 18, 2004.
12. KDN effluent/nicotine extract design. February 26, 1991. RJ Reynolds. Bates no. 508029619/9619. Available at: http://legacy.library.ucsf.edu/tid/ vfj13a00. Accessed June 18, 2004.
13. Flinchum G. German high nicotine extract. November 22, 1993. RJ Reynolds. Bates no. 510783956/3956. Available at: http://legacy.library.ucsf.edu/tid/ bju53d00. Accessed June 18, 2004.
14. Additional investment and production cost calculations for the Winston-Salem cast sheet when a nicotine extract is added. December 8, 1993. RJ Reynolds. Bates no. 512596452/6454. Available at: http://legacy.library.ucsf. edu/tid/bfj33d00. Accessed June 18, 2004.
15. Cigarette additive list [no longer available at following URL; the 1994 list can be found at http://en.wikipedia.org/wiki/ List_of_additives_in_cigarettes]. http://www.drugs.indiana.edu/resources/ druginfo/drugs/tobaccoadditives.html. Accessed July 10, 2005.
16. National Center for Chronic Disease Prevention and Health Promotion. Tobacco products fact sheet. Available at: http://www.cdc.gov/tobacco/sgr/ sgr_2000/factsheets/factsheets_tobacco. htm. Accessed July 9, 2005.
17. Scientific statement from the VDC Working Group. Philip Morris. Bates no. 2078377943/7949. Available at: http://legacy.library.ucsf.edu/tid/tqs72c00. Accessed July 1, 2004.
18. Bates C, Jarvis M, Connolly G. Tobacco additives: cigarette engineering and nicotine addiction. Bates no. 83452276. Available at: http://www.ash.org.uk/ html/regulation/html/additives.html. Accessed July 10, 2003.
19. Keithly L, Ferris Wayne G, Cullen DM, Connolly GN. Industry research on the use and effects of levulinic acid: a case study in cigarette additives. Nicotine Tob Res. 2005;7:761-771.
20. Browne CL. The Design of Cigarettes. 3rd ed. Charlotte, NC: Filter Products Division, Celanese Corp; 1990.
21. Fowles J. Chemical factors influencing the addictiveness and attractiveness of cigarettes in New Zealand. Available at: http://www.ndp.govt. nz/tobacco/documents/cigaretteaddictiveness.pdf. Accessed May 14, 2006.
22. Connolly GN, Wayne GD, Lymperis D, Doherty MC. How cigarette additives are used to mask environmental tobacco smoke. Tob Control. 2000;9:283-291.
23. Gauvin PN, Goodman BL. Project 4009: development smoke studies. Philip Morris. Bates no. 1002813747/3833. Available at: http://legacy.library.ucsf.edu/ tid/lyi98e00. Accessed August 1, 2004.
24. Operational plan for sidestream odor 930000. Philip Morris. Bates no. 2063097509/7510. Available at: http://legacy.library.ucsf.edu/tid/jxk42d00. Accessed August 2, 2004.
25. Holbert N. Awareness study. March 30, 1981. RJ Reynolds. Bates no. 500622125/2137. Available at: http://legacy.library.ucsf.edu/tid/egg31d00. Accessed July 10, 2004.
26. Johnson JL, Purvis AR. ETS: public opinion polls and surveys on awareness. December 6, 2001. Philip Morris. Bates no. 2085287533/7538. Available at: http://legacy.library.ucsf.edu/tid/ykm10c00. Accessed July 10, 2004.
27. Monroe BA. Patent search: masking sidestream odor. February 22, 1989. Philip Morris. Bates no. 2028661012/ 1014. Available at: http://legacy.library. ucsf.edu/tid/avu42d00. Accessed July 10, 2004.
28. Legacy Tobacco Documents Library Web site. Available at: http://www.legacy.library.ucsf.edu. Accessed November 14, 2005.
29. Information on herbs and other supplements. Available at: http://www.mskcc.org/aboutherbs. Accessed July 1, 2004.
30. US Patent and Trademark Office Web site. Available at: http://uspto.gov. Accessed July 1, 2004.
31. Glantz SA, Slade J, Bero L, Hanauer P, Barnes DE. The Cigarette Papers. Berkeley and Los Angeles: University of California Press; 1998.
32. Juvonen RO, Gynther J, Pasanen M, Alhava E, Poso A. Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases (CYP2A5 and CYP2A6). Xenobiotica. 2000;30:81-92.
33. Charles JL, Davies B, DeNoble VJ, Horn JL, Mele PC. Behavioral pharmacology annual report. Philip Morris. Bates no. 2022144128/4211. Available at: http://legacy.library.ucsf.edu/tid/bly44e00. Accessed July 7, 2004.
34. DeNoble VJ, Harris CM, Horn J, Mele PC. Reinforcing activity of acetaldehyde [abstract]. Philip Morris. Bates no. 2071670753/0755. Available at: http://legacy.library.ucsf.edu/tid/can26c00. Accessed July 10, 2004.
35. Deines WH, Frank DM. Addition of sugar, sorbitol and DAP to WTS increases tar, nicotine and puff number on Viceroy 84. September 9, 1974. Brown and Williamson. Bates no. 680113252. Available at: http://legacy.library.ucsf.edu/ tid/izb50f00. Accessed August 2, 2004.
36. Dunn WL. Plans and objectives - 820000. November 5, 1981. Brown and Williamson. Bates no. 680903087/3095. Available at: http://legacy.library.ucsf. edu/tid/cdm93f00. Accessed August 2, 2004.
37. Gullotta FP, Hayes CS. Project number: 1620 electrophysiological studies pattern-reversal evoked potentials (PREPs). March 3, 1991. Philip Morris. Bates no. 2056128339. Available at: http://legacy.library.ucsf.edu/tid/fdl36e00. Accessed June 10, 2003.
38. Gullotta FP. Summary of research conducted at Philip Morris. September 22, 1994. Philip Morris. Bates no. 2056128216/8223. Available at: http://legacy.library.ucsf.edu/tid/xsw83c00. Accessed August 2, 2004.
39. Gullotta FP, Hayes CS, Martin BR. When nicotine is not nicotine. Philip Morris. Bates no. 2063127742/7747. Available at: http://legacy.library.ucsf.edu/ tid/yef33e00. Accessed July 5, 2004.
40. Gullotta F, Hayes C, Martin B. The effects of nicotine and menthol on electrophysiological and subjective responses. June 27, 1991. Philip Morris. Bates no. 2028817734/7740. Available at: http://legacy.library.ucsf.edu/tid/ rfp12e00. Accessed August 2, 2004.
41. P1-N2 amplitude change. Philip Morris. Bates no. 2062170324/0330. Available at: http://legacy.library.ucsf.edu/tid/oxg33e00. Accessed July 5, 2004.
42. Beta-Carotene Study Group graphics: safer cigarette. April 27, 1993. RJ Reynolds. Bates no. 512228142/8146. Available at: http://legacy.library.ucsf. edu/tid/eeb43d00. Accessed June 21, 2004.
43. Beta-Carotene Study Group vision. September 9, 1992. RJ Reynolds. Bates no. 508303718/3718. Available at: http://legacy.library.ucsf.edu/tid/mmw93d00. Accessed August 2, 2004.
44. Beta carotene AT XB-tar modification. May 18, 1993. RJ Reynolds. Bates no. 510354645/4757. Available at: http://legacy.library.ucsf.edu/tid/fof63d00. Accessed December 20, 2003.
45. Beta-Carotene Study Group opportunity. October 23, 1992. RJ Reynolds. Bates no. 508698033/8033. Available at: http://legacy.library.ucsf.edu/tid/ abb93d00. Accessed August 2, 2004.
46. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029-1035.
47. Mitigant enriched cigarette-reduced oxidative stress cigarette. RJ Reynolds. Bates no. 512290169/0169. Available at: http://legacy.library.ucsf. edu/tid/gww33d00. Accessed June 16, 2004.
48. Mitigant technical review. RJ Reynolds. Bates no. 512278126/8144. Available at: http://legacy.library.ucsf.edu/tid/gzl38c00. Accessed June 16, 2004.
49. McGee CD. Monthly highlights: mitigant research program. March 18, 1994. RJ Reynolds. Bates no. 512231181/1181. Available at: http://legacy.library.ucsf. edu/tid/dua43d00. Accessed June 18, 2004.
50. Mitigant article summaries. May 6, 1994. RJ Reynolds. Bates no. 510663988/4019. Available at: http://legacy.library.ucsf.edu/tid/kou87c00. Accessed June 18, 2004.
51. Simmons WS. The "mitigant" approach to modifying biological activity of tobacco smoke. June 20, 1992. RJ Reynolds. Bates no. 510812596/2597. Available at: http://legacy.library.ucsf.edu/tid/pbt53d00. Accessed June 15, 2004.
52. Biological testing of mitigant efficacy. RJ Reynolds. Bates no. 511111742/1742. Available at: http://legacy.library.ucsf.edu/tid/aah38c00. Accessed June 15, 2004.
53. Mitigant Steering Committee. Meeting announcement. July 28, 1993. RJ Reynolds. Bates no. 508695980/ 5981. Available at: http://legacy.library.ucsf. edu/tid/bmb93d00. Accessed June 15, 2004.
54. Biological testing/oxidative mitigant project. September 22, 1993. RJ Reynolds. Bates no. 510067221/7230. Available at: http://legacy.library.ucsf. edu/tid/uxm63d00. Accessed June 16, 2004.
55. McGee CD. Monthly highlights: mitigant research program. October 18, 1993. RJ Reynolds. Bates no. 512231185/1185. Available at: http://legacy. library.ucsf.edu/tid/hua43d00. Accessed June 16, 2004.
56. Dube M. Mitigant research: protocept development projects. December 15, 1993. RJ Reynolds. Bates no. 512396717/6724. Available at: http://legacy. library.ucsf.edu/tid/ddr33d00. Accessed June 17, 2004.
57. Mitigant team objective. January 26, 1994. RJ Reynolds. Bates no. 512076415/6418. Available at: http://legacy.library.ucsf.edu/tid/pnf43d00. Accessed June 16, 2004.
58. Status of mitigant team activities and recommendations. February 17, 1994. RJ Reynolds. Bates no. 508698026/8027. Available at: http://legacy. library.ucsf.edu/tid/yab93d00. Accessed June 17, 2004.
59. Wrona MZ, Waskiewicz J, Han QP, Han J, Li H, Dryhurst G. Putative oxidative metabolites of 1-methyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline of potential relevance to the addictive and neurodegenerative consequences of ethanol abuse. Alcohol. 1997;14:213-223.
60. Fowles J, Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob Control. 2003;12:424-430.
61. Bates M, Fowles J, Noiton D. The chemical constituents in cigarettes and cigarette smoke: priorities for harm reduction. Philip Morris. Bates no. 2505913406/3471. Available at: http://legacy.library.ucsf.edu/tid/nsn81c00. Accessed June 21, 2004.
62. Food Extract Manufacturers' Association. Scientific literature review of salicylates and salicylaldehyde in flavor usage. Lorillard. Bates no. 89403838/ 3968. Available at: http://legacy.library.ucsf.edu/tid/fom64c00. Accessed June 15, 2004.
63. Hurt R, Robertson C. Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota tobacco trial. JAMA. 1998;280:1173-1181.
64. Sokmen A, Vardar-Unlu G, Polissiou M, Daferera D, Sokmen M, Donmez E. Antimicrobial activity of essential oil and methanol extracts of Achillea sintenisii hub. Mor. (Asteraceae). Phytother Res. 2003;17:1005-1010.
65. Hasani A, Pavia D, Toms N, Dilworth P, Agnew JE. Effect of aromatics on lung mucociliary clearance in patients with chronic airways obstruction. J Altern Complement Med. 2003;9:243-249.
66. Juergens UR, Dethlefsen U, Steinkamp G, Gillissen A, Repges R, Vetter H. Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial. Respir Med. 2003;97:250-256.
67. Moteki H, Hibasami H, Yamada Y, Katsuzaki H, Imai K, Komiya T. Specific induction of apoptosis by 1,8-cineole in two human leukemia cell lines, but not in a human stomach cancer cell line. Oncol Rep. 2002;9:757-760.
68. Santos FA, Rao VS. Antiinflammatory and antinociceptive effects of 1,8-cineole, a terpenoid oxide present in many plant essential oils. Phytother Res. 2000;14:240-244.
69. Steele RH. Clove oil, eugenol, isoeugenol, and methyl eugenol. July 17, 1985. RJ Reynolds. Bates no. 504239346/9361. Available at: http://legacy. library.ucsf.edu/tid/aen58d00. Accessed June 18, 2004.
70. Carcinogenesis studies of eugenol in F344/N rats and B6C3F1 mice (feed studies). RJ Reynolds. Bates no. 521764618/4618. Available at: http://legacy.library.ucsf.edu/tid/mrd50d00. Accessed June 18, 2004.
71. Eugenol. June 9, 2000. RJ Reynolds. Bates no. 521764619/4619. Available at: http://legacy.library.ucsf.edu/tid/ymh20d00. Accessed June 18, 2004.
72. Suber R. Re: pulegone and eugenol. June 14, 2000. RJ Reynolds. Bates no. 521533572/3572. Available at: http://legacy.library.ucsf.edu/tid/qoy20d00. Accessed June 18, 2004.
73. Grundschober F, Techn S. Information letter 1265 - USA: methyl eugenol. RJ Reynolds. Bates no. 524434480/ 4480. Available at: http://legacy.library. ucsf.edu/tid/ayu03c00. Accessed June 18, 2004.
74. NTP technical report on the carcinogenesis bioassay of eugenol. January 12, 1981. Brown and Williamson. Bates no. 504001029/1051. Available at: http://legacy.library.ucsf.edu/tid/mqt24f00. Accessed June 18, 2004.
75. Yazlovitskaya EM, Melnykovych G. Selective farnesol toxicity and translocation of protein kinase C in neoplastic HeLa-S3K and non-neoplastic CF-3 cells. Cancer Lett. 1995;88:179-183.
76. Kai K, Komine K, Asai K, et al. Anti-inflammatory effects of intramammary infusions of glycyrrhizin in lactating cows with mastitis caused by coagulase-negative staphylococci. Am J Vet Res. 2003;64:1213-1220.
77. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi. 2000;120:849-862.
78. Ohtsuki K, Iahida N. Inhibitory effect of glycyrrhizin on polypeptide phosphorylation by polypeptide-dependent protein kinase (kinase P) in vitro. Biochem Biophys Res Commun. 1988;157:597-604.
79. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998;12:199-205.
80. Hsiang CY, Lai IL, Chao DC, Ho TY. Differential regulation of activator protein 1 activity by glycyrrhizin. Life Sci. 2002;70:1643-1656.
81. Lawrence BM. Eugenol (eugenyl) glucoside. August 26, 1991. RJ Reynolds. Bates no. 509734218/4218. Available at: http://legacy.library.ucsf.edu/tid/ ajz63d00. Accessed June 18, 2004.
82. Tuttleolm D, Reynolds JH, Rees DC. Eugenol glucoside as an aroma precursor. April 2, 1992. RJ Reynolds. Bates no. 509010630/0631. Available at: http://legacy.library.ucsf.edu/tid/gal83d00. Accessed June 18, 2004.
83. Opdyke DLJ. Isovaleric acid. Lorillard. Bates no. 87500751/0753. Available at: http://legacy.library.ucsf.edu/tid/zuh98c00. Accessed July 10, 2004.
84. Nicotine levulinic enhancement of (3H)-nicotine binding to nicotinic receptors in rat brain. RJ Reynolds. Bates no. 507863526/3535. Available at: http://legacy.library.ucsf.edu/tid/epk14d00. Accessed June 20, 2004.
85. Gullotta F, Hayes C, Martin B. The effects of nicotine and menthol on electrophysiological and subjective responses. June 27, 1991. Philip Morris. Bates no. 2028817734/7740. Available at: http://legacy.library.ucsf.edu/tid/ rfp12e00. Accessed August 2, 2004.
86. Phytochemical and ethnobotanical database. Available at: http://www.ars-grin.gov/duke/. Accessed July 1, 2004.
87. Farone W. Pyridine studies. April 11, 1996. Philip Morris. Bates no. 2064791028. Available at: http://legacy.library.ucsf.edu/tid/kgn93c00. Accessed June 25, 2004.
88. Salicylaldehyde. September 8, 1994. RJ Reynolds. Bates no. 515165144/5147. Available at: http://legacy.library.ucsf.edu/tid/kli01d00. Accessed August 2, 2004.
89. Written statement of Victor John DeNoble. April 27, 1994. Philip Morris. Bates no. 511407704/7710. Available at: http://legacy.library.ucsf.edu/tid/ fxp31d00. Accessed August 2, 2004.
90. Baker R, Carling WR, Leeson PD, Smith JD. US patent 5,231,102: tetra-hydroquinoline derivatives useful for neurodegenerative disorders. July 27, 1993. RJ Reynolds. Bates no. 515822483/2483. Available at: http://legacy.library.ucsf.edu/tid/bvg92d00. Accessed August 8, 2004.
91. DeNoble J. Written statement of Victor DeNoble, PhD. Congressional testimony. American Tobacco. Bates no. 980232257/226. Available at: http://legacy.library.ucsf.edu/tid/ysn84f00. Accessed June 6, 2007.
92. Hadley S, Petry J. Valerian. Am Fam Physician. 2003;67:1755-1758.
93. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol. 1999;51:505-512.
94. Teychenne PF, Walters I, Claveria LE, et al. The encephalopathic action of five-carbon-atom fatty acids in the rabbit. Clin Sci Mol Med. 1976;50:463-472.
95. Hendriks H, Bos R, Allersma DP, Malingre TM, Koster AS. Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis. Planta Med. 1981;42:62-68.
96. Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H] flunitrazepam binding, synaptosomal [3H] GABA uptake, and hippocampal [3H] GABA release. Neurochem Res. 1999;24:1373-1378.
97. Biosource project review. RJ Reynolds. Bates no. 508303793/3808. Available at: http://legacy.library.ucsf.edu/tid/xmw93d00. Accessed August 2, 2004.
98. RJR/Biosource joint venture agreement. April 3, 1992. RJ Reynolds. Bates no. 508303810/3826. Available at: http://legacy.library.ucsf.edu/tid/ymw93d00. Accessed August 2, 2004.
99. Biotechnology research program: update and review. RJ Reynolds. Bates no. 508303728/3742. Available at: http://legacy.library.ucsf.edu/tid/smw93d00. Accessed August 2, 2004.
100. Beta carotene. RJ Reynolds. Bates no. 522541730/1752. Available at: http://legacy.library.ucsf.edu/tid/xgc92a00. Accessed August 2, 2004.
101. Banzhaf JF. Secret cigarette industry tape recordings filed today with FDA describe nicotine delivery, and removal of carcinogens. Bates no. 2061693331/3337. Available at: http://legacy.library.ucsf.edu/tid/uyk32d00. Accessed August 2, 2004.
102. The Health Consequences of Smoking - The Changing Cigarette: A Report of the Surgeon General. Washington, DC: US Department of Health and Human Services; 1981.
103. Farone WA. Idea session on beneficial additives. February 16, 1981. Philip Morris. Bates no. 1003395096/5101. Available at: http://legacy.library. ucsf.edu/tid/kta28e00. Accessed May 17, 2005.
104. McDonald CE, Rosenberg MD. Technical Information Section nontobacco biological/botanical smoking materials. October 19, 1983. Philip Morris. Bates no. 1000082599/2616. Available at: http://legacy.library.ucsf.edu/tid/kpx64e00. Accessed May 17, 2005.
105. Finberg J. Smoking composition. Available at: http://www.uspto.gov. Accessed April 10, 2006.
106. Rodriguez BK, Bellin SA, Snyder GA. Niacin and nicacinamide in fluecured cigarette smoke condensate. August 10, 1960. Philip Morris. Bates no. 500600367/0381. Available at: http://legacy.library.ucsf.edu/tid/pnx69d00. Accessed May 29, 2005.
107. Falk KG. The absorption of niacin in the smoking of cigarettes. December 19, 1944. Philip Morris. Bates no. 1003072792/2796. Available at: http://legacy.library.ucsf.edu/tid/sqm25e00. Accessed May 29, 2005.
108. Debardeleben MZ. Commercial production of niacin (nicotinic acid). July 24, 1989. Philip Morris. Bates no. 2022203224/3225. Available at: http://legacy.library.ucsf.edu/tid/jys58e00. Accessed May 29, 2005.
109. Job procedure: chlorogenic acid and rutin by high pressure liquid chromatography E 54. Philip Morris. Bates no. 2074114452/4454. Available at: http://legacy.library.ucsf.edu/tid/bpn45c00. Accessed May 29, 2005.
110. Inskeep GE. Patents on vitamins and therapeutic ingredients in cigarettes. December 12, 1966. Philip Morris. Bates no. 2028665601. Available at: http://legacy.library.ucsf.edu/tid/sqm25e00. Accessed May 29, 2005.
111. Monroe B. Medicated cigarettes. January 6, 1988. Philip Morris. Bates no. 2023132355/2401. Available at: http://legacy.library.ucsf.edu/tid/awy18d00. Accessed May 29, 2005.
112. Patent list: medicated cigarettes. January 6, 1988. Philip Morris. Bates no. 500600367/0381. Available at: http://legacy.library.ucsf.edu/tid/btp04e00. Accessed May 29, 2005.
113. Chung H, Aldridge JC. Pyrolytic study of eugenol glucoside. August 21, 1981. RJ Reynolds. Bates no. 508009154/9157. Available at: http://legacy. library.ucsf.edu/tid/nwx04d00. Accessed June 18, 2004.
114. Pankow JF, Tavakoli AD, Luo W, Isabelle LM. Percent free base nicotine in the tobacco smoke particulate matter of selected commercial and reference cigarettes. Chem Res Toxicol. 2003;16:1014-1018.
115. Brauer LH, Behm FM, Lane JD, Westman EC, Perkins C, Rose JE. Individual differences in smoking reward from de-nicotinized cigarettes. Nicotine Tob Res. 2001;3:101-109.
116. Fleming T. PDR for Herbal Medicines. 2nd ed. Montvale, NJ: Medical Economics Co; 2000.
117. Virtamo J, Pietinen P, Huttunen JK, et al. Incidence of cancer and mortality following alpha-tocopherol and betacarotene supplementation. JAMA. 2003;290:476-485.